**Research Disclaimer:** This article is intended for research and informational purposes only. BPC-157 and TB-500 are not approved by the FDA or Health Canada for human use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of any product. These compounds are available for legitimate laboratory and research use only.
BPC-157 and TB-500 are two of the most discussed peptides in the research compound space. Each has been studied for tissue repair and recovery properties, each has attracted mainstream attention in 2025–2026, and each is operating under evolving regulatory scrutiny in North America and internationally.
Together, they’re sometimes called the “Wolverine Stack” — a term that’s useful for search purposes but does little to clarify what the compounds actually are, how they differ, or what the current evidence base actually shows. This article separates the science from the hype.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a naturally occurring protein found in human gastric juice. It is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that does not exist as a standalone compound in the body — it is a research tool derived from a larger protein.
BPC-157 has been studied primarily in animal models for its effects on:
- Tendon and ligament healing — multiple rodent studies show accelerated collagen synthesis and tensile strength recovery in surgically transected tendons
- Gastrointestinal tissue repair — the original area of study; BPC-157 shows protective effects in models of gut inflammation, ulceration, and anastomotic healing
- Muscle tissue recovery — animal models suggest effects on myosin-heavy chain expression and muscle repair after crush injury
- Neurological recovery — preclinical data on traumatic brain injury and peripheral nerve repair; early signals in stroke models
The evidence gap: The vast majority of BPC-157 research — published research, not anecdotes — is in rodents. As of May 2026, there are no completed large-scale randomized controlled trials in humans. Several small human studies exist, primarily in gastroenterology, but none have been conducted with the rigor required for regulatory approval. This is the critical context that is often missing from popular coverage.
What Is TB-500?
TB-500 is a synthetic version of thymosin beta-4 (Tβ4), specifically a fragment corresponding to amino acids 17–23 of the full 43-amino-acid thymosin beta-4 protein. The confusion between TB-500 and thymosin beta-4 is one of the most persistent misunderstandings in the peptide research community.
- Thymosin beta-4 (Tβ4): Full 43-amino-acid protein, naturally occurring, plays roles in actin polymerization, cell migration, angiogenesis, and tissue repair
- TB-500: Synthetic 7-amino-acid fragment (Ac-LKKTETQ), not identical to the full protein
Why does this matter? Because research results generated with thymosin beta-4 cannot be directly attributed to TB-500 without specific evidence that the fragment retains the same biological activity as the full protein. Some studies have shown the fragment to be biologically active in specific contexts; others have not replicated the full-protein findings. The literature must be read carefully with this distinction in mind.
TB-500 research areas include:
- Wound healing and angiogenesis — the best-supported area, with animal data showing accelerated wound closure and vascular formation
- Cardiac tissue repair — preclinical studies, including myocardial infarction models, showing potential cardioprotective effects
- Corneal healing — one of the more advanced human-adjacent research areas, with studies in animal corneal injury models
- Muscle and tendon recovery — similar to BPC-157, primarily rodent data
BPC-157 vs TB-500: Key Differences
| Feature | BPC-157 | TB-500 |
|—|—|—|
| Compound type | Synthetic pentadecapeptide (15 AA) | Synthetic Tβ4 fragment (7 AA) |
| Origin | Derived from gastric protein sequence | Fragment of thymosin beta-4 |
| Primary research area | GI repair, tendon, muscle | Wound healing, cardiac, corneal |
| Animal study volume | High — extensive rodent literature | Moderate — rodent and some equine |
| Human data | Very limited | Very limited |
| WADA status | Banned (S0 category) | Banned (S0 category) |
| FDA status | Unapproved, Cat. 2 per PCAC history | Unapproved, PCAC review July 2026 |
| Canadian regulatory status | Unauthorized drug — not for human use | Unauthorized drug — not for human use |
Both compounds share the same fundamental limitation: they have extensive preclinical data and essentially no regulatory-standard human clinical evidence. They are both on the World Anti-Doping Agency (WADA) banned substances list under Category S0 (non-approved substances), meaning athletes subject to WADA testing cannot use them regardless of performance intent.
The Wolverine Stack: What It Means and Why It Trends
The term “Wolverine Stack” refers to the combined use of BPC-157 and TB-500 for recovery purposes — named after the Marvel character known for regenerative healing. It is a community-coined term, not a clinical designation.
From a search behavior standpoint, “Wolverine Stack” serves as a bridge keyword: users who know the pop-culture reference but not the compound names, and users who know one compound but are looking for recovery stacks. It’s a useful term for content discovery, but it should be understood as informal shorthand.
From a research standpoint, there is essentially no published literature on the combination of BPC-157 and TB-500 in any model system. The rationale for combining them is theoretical, based on their distinct proposed mechanisms (BPC-157 for GI/tendon signaling via growth hormone and nitric oxide pathways; TB-500 for actin-mediated cell migration and angiogenesis via Tβ4-fragment activity). Whether these effects are additive, synergistic, or independent when combined has not been studied.
FDA Status in 2026: What Has Changed
BPC-157:
BPC-157 has been classified as a Category 2 substance by the FDA’s Pharmacy Compounding Advisory Committee (PCAC), meaning it was nominated for bulk compounding use and reviewed but was not approved for inclusion on the bulks list. This designation means that compounding pharmacies cannot legally compound BPC-157 for human use in the United States.
The compound is not an approved new drug and has not been the subject of a successful IND (Investigational New Drug) application that has progressed to Phase 2 or 3 trials as of May 2026. Some researchers have noted that the proprietary research originating in Croatia (PLIVAmed) never moved into a conventional regulatory development pathway.
TB-500:
As of April 2026, the FDA Federal Register listed TB-500 forms for upcoming PCAC review, scheduled for July 2026. This creates a significant regulatory milestone: depending on PCAC recommendations and subsequent FDA action, TB-500’s compounding status could change by late 2026. The July PCAC meeting is an important date for anyone tracking this space.
Canada (WebberScience market context):
In Canada, both BPC-157 and TB-500 are unauthorized drugs — they are not approved by Health Canada for human use and cannot be legally sold for human consumption. They are available for legitimate laboratory and research use, consistent with applicable Canadian research regulations.
What the Evidence Actually Supports (and What It Doesn’t)
Being rigorous about what the research literature shows matters, particularly given the volume of anecdotal and hype-driven content in this space.
Reasonably supported (in animal models):
- BPC-157 accelerates tendon-to-bone healing in rodent models under controlled conditions
- TB-500 (or Tβ4) promotes wound closure and angiogenesis in multiple animal injury models
- Both compounds appear well-tolerated in rodent studies at research doses, with no major acute toxicity signals
Not established:
- Efficacy in humans at any dose (no completed Phase 3 trials for either compound)
- Optimal dose, frequency, or route of administration for human applications
- Long-term safety in any population
- Whether the results of animal models translate to human physiology at practical doses
Misrepresented in popular coverage:
- BPC-157 is frequently described as having human trial evidence — typically, this refers to small, early-phase studies in gastroenterology that do not address musculoskeletal or neurological claims
- TB-500 is frequently treated as interchangeable with thymosin beta-4 — the fragment is biologically distinct and the research literature must be parsed accordingly
Frequently Asked Questions
Q: Is BPC-157 legal to buy in Canada?
BPC-157 is an unauthorized drug in Canada and is not approved by Health Canada for human use. It may be available for legitimate laboratory or research purposes through regulated research supply channels. It cannot be sold for human consumption. Always verify the regulatory status for your specific use case.
Q: What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 (Tβ4) is the full 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment (the LKKTETQ sequence from positions 17–23). They are structurally different compounds. Research findings with Tβ4 do not automatically apply to TB-500, and the two should not be treated as equivalent.
Q: What is the Wolverine Stack?
The Wolverine Stack is an informal community term for the combined use of BPC-157 and TB-500. It has no clinical definition and there is no published research on the combination. The term is widely used in biohacker and research compound communities but is not a recognized research protocol.
Q: What is PCAC and why does the July 2026 meeting matter for TB-500?
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory committee that reviews substances nominated for the bulk compounding lists. The July 2026 PCAC meeting is scheduled to include review of TB-500 forms. Depending on the committee’s recommendations and subsequent FDA action, the legal compounding status of TB-500 in the U.S. could be affected.
Q: Are BPC-157 and TB-500 banned in sports?
Yes. Both compounds are listed under WADA’s Category S0 (Prohibited Substances — Non-Approved Substances). Athletes subject to WADA testing cannot use them regardless of the reason or context.
Conclusion
BPC-157 and TB-500 are among the most studied research peptides in the recovery and tissue repair category. The animal model literature is substantive, but the human evidence base remains thin, and both compounds operate outside of approved regulatory pathways in the U.S. and Canada.
For researchers in the Canadian market, the key framework is this: both compounds are unauthorized drugs, available only for legitimate research use, with evolving regulatory status in the U.S. that could shift after the July 2026 PCAC meeting for TB-500 and following any subsequent action on BPC-157’s Category 2 classification.
The Wolverine Stack framing gets clicks — but the actual research demands more precision. We’ll continue tracking regulatory developments and updating this overview as new data emerges.
This content is produced for informational and research purposes only. BPC-157 and TB-500 are not approved for human use by the FDA or Health Canada. Nothing here constitutes medical advice. All research use must comply with applicable laws and regulations.